NLRP3 and ischemic cardiomyopathy: With the NLRP3 inflammasome being relevant in immune and non-immune cells of the vasculature and myocardium, modulation of low-grade chronic inflammation underlying atherosclerosis, coronary artery disease and remodelling in ischemic cardiomyopathy could be achieved with targeted NLRP3 inhibition [12, 13, 16].